Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Latest From Hanwha Corp

Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies

South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.

Research & Development South Korea

Korea Mulls New Biosimilar Guidelines As Pipeline Surges

As more biosimilar products are set to be released in South Korea, with a hefty number of ongoing late-stage clinical trials, the country is seeking to introduce a new separate guideline for insulin biosimilars. While South Korea has introduced biosimilar guidelines relatively earlier than some others, a local institute suggests these still need to be improved, pointing to a lack of clarity and implementation issues.

BioPharmaceutical South Korea

Korean Green Light For Samsung Bioepis’s Biosimilar Etanercept

Within just three and a half years since its establishment, Samsung Bioepis has received its first regulatory approval for a biosimilar, meaning the Samsung Group affiliate is now set to release its version of Amgen’s Enbrel (etanercept) in South Korea late this year or early next. It will be the fourth locally developed biosimilar to hit the domestic market and is expected to be priced at about a 30% discount.

BioPharmaceutical South Korea

Biologics World Korea: Counting On A Paradigm Shift In Biologics Market

Biopharmaceutical experts from around the world gathered in Seoul at the recent Biologics World Korea 2015, at which a group of panelists discussed the strategic direction of the biologics industry in Asia and a paradigm shift in the global biologics market.

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Contract Manufacturing Organization
  • Other Names / Subsidiaries
    • DreamPharma Corp.
    • Hanwha Chemical Corporation
    • Hanwha Europe GmbH
    • Hanwha Group
    • Hanwha Living and Creative Corporation
    • Yeochun NCC